Advisory Board February 25, 2025
Last week, FDA declared that GLP-1 drugs for diabetes and weight loss are no longer in shortage — a decision that could have widespread impacts on companies offering compounded versions of the drugs.
The 5 biggest weight management drug questions (and our answers
GLP-1 drugs no longer in shortage
In October, FDA announced that Eli Lilly’s GLP-1 drug tirezepatide was no longer in shortage after the company determined that its manufacturing capacity could meet “present and projected” demand for the drug. Tirezepatide is also known by its brand names Zepbound and Mounjaro.
Although FDA initially reevaluated its decision to remove tirzepatide from its shortages list following a lawsuit from the Outsourcing Facilities Association, the agency later reaffirmed that the GLP-1...
Today's Sponsors
Today's Sponsor